ES2135123T3 - Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos. - Google Patents

Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos.

Info

Publication number
ES2135123T3
ES2135123T3 ES96103701T ES96103701T ES2135123T3 ES 2135123 T3 ES2135123 T3 ES 2135123T3 ES 96103701 T ES96103701 T ES 96103701T ES 96103701 T ES96103701 T ES 96103701T ES 2135123 T3 ES2135123 T3 ES 2135123T3
Authority
ES
Spain
Prior art keywords
deterioration
deprenyl
mammals
immune system
delay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96103701T
Other languages
English (en)
Inventor
Norton W Milgram
David R Stevens
Gwendolyn O Ivy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deprenyl Animal Health Inc
Original Assignee
Deprenyl Animal Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27076843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135123(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/576,011 external-priority patent/US5151449A/en
Application filed by Deprenyl Animal Health Inc filed Critical Deprenyl Animal Health Inc
Application granted granted Critical
Publication of ES2135123T3 publication Critical patent/ES2135123T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Thin Film Transistor (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pulse Circuits (AREA)

Abstract

EL L-DEPRENIL Y LAS FORMULAS ANALOGAS, FARMACEUTICAMENTE ACEPTABLES, DEL MISMO, SE UTILIZAN A NIVELES Y FRECUENCIA DE DOSIFICACION CONCRETOS PARA RETARDAR EL DETERIORO CON LA EDAD DE LA FUNCION DEL SISTEMA DE INMUNIZACION EN LOS MAMIFEROS. EL TRATAMIENTO PUEDE SER ESPECIALMENTE UTIL PARA ANIMALES DOMESTICOS COMO PERROS Y GATOS.
ES96103701T 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos. Expired - Lifetime ES2135123T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/576,011 US5151449A (en) 1990-08-31 1990-08-31 Use of L-deprenyl for retention of specific physiological functions
US64345291A 1991-01-18 1991-01-18

Publications (1)

Publication Number Publication Date
ES2135123T3 true ES2135123T3 (es) 1999-10-16

Family

ID=27076843

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91302820T Expired - Lifetime ES2097790T3 (es) 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro debido al envejecimiento.
ES96103701T Expired - Lifetime ES2135123T3 (es) 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES91302820T Expired - Lifetime ES2097790T3 (es) 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro debido al envejecimiento.

Country Status (15)

Country Link
US (2) US5276057A (es)
EP (2) EP0732101B1 (es)
JP (3) JP2819072B2 (es)
AT (2) ATE149350T1 (es)
AU (1) AU633714B2 (es)
BR (1) BR9103506A (es)
CA (1) CA2039194C (es)
DE (2) DE69124875T2 (es)
DK (2) DK0732101T3 (es)
ES (2) ES2097790T3 (es)
GR (2) GR3022971T3 (es)
ID (1) ID19492A (es)
MX (1) MX9100067A (es)
MY (2) MY124210A (es)
NZ (1) NZ238277A (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565495A (en) * 1990-08-31 1996-10-15 Deprenyl Animal Health, Inc. Method for survival curve shifting in dogs
US5561163A (en) * 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
CA2107552C (en) * 1991-04-04 2001-08-28 William G. Tatton Use of deprenyl to maintain, prevent loss, or recover nerve cell function
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
FR2704756B1 (fr) * 1993-05-04 1995-07-28 Sanofi Elf Utilisation de la sélégiline en médecine vétérinaire.
DK0623344T3 (da) * 1993-05-04 2000-12-18 Ceva Sante Animale Anvendelse af selegilin i veterinær medicin
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
JP3036847B2 (ja) 1995-01-13 2000-04-24 サマーセット・ファーマシューティカルズ・インコーポレイテッド デスメチルセレギリンを用いる方法および医薬組成物
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
CA2212412A1 (en) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
IL122484A0 (en) 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
ATE222101T1 (de) 1998-03-16 2002-08-15 Somerset Pharmaceuticals Inc Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
US20030212144A1 (en) * 2001-07-18 2003-11-13 Mohankumar Sheba J.J. Method for inducing an estrous cycle and pregnancy in a female mammal
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
WO2005051371A1 (en) * 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
AU2010343129B2 (en) * 2009-12-29 2013-05-16 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
JP6045347B2 (ja) 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
CN103860503A (zh) * 2012-12-10 2014-06-18 天津市汉康医药生物技术有限公司 一种治疗帕金森病的缓释药物组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA871155A (en) * 1971-05-18 Chinoin Gyogyszer-Es Vegyeszeti Termekek Gyara Rt Optically active phenyl isopropylamine derivatives having pharmaceutical properties and their preparation
HU187775B (en) * 1982-07-14 1986-02-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu New process for producing propargile-amines of pharmaceutical activity
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US4880883A (en) * 1987-06-03 1989-11-14 Wisconsin Alumni Research Foundation Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5192808A (en) * 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
JPH09328423A (ja) 1997-12-22
JP2884501B2 (ja) 1999-04-19
AU633714B2 (en) 1993-02-04
ES2097790T3 (es) 1997-04-16
ATE181501T1 (de) 1999-07-15
DE69124875D1 (de) 1997-04-10
DE69131386T2 (de) 1999-11-25
JPH04230624A (ja) 1992-08-19
CA2039194A1 (en) 1992-03-01
MX9100067A (es) 1992-04-01
JP2884500B2 (ja) 1999-04-19
EP0732101A1 (en) 1996-09-18
MY110217A (en) 1998-03-31
BR9103506A (pt) 1992-05-12
GR3031263T3 (en) 1999-12-31
EP0473252A2 (en) 1992-03-04
DK0473252T3 (da) 1997-09-15
EP0732101B1 (en) 1999-06-23
JPH09328422A (ja) 1997-12-22
DK0732101T3 (da) 1999-11-22
HK1011611A1 (en) 1999-07-16
DE69124875T2 (de) 1997-06-26
NZ238277A (en) 1993-10-26
ID19492A (id) 1998-07-16
ATE149350T1 (de) 1997-03-15
US5387615A (en) 1995-02-07
MY124210A (en) 2006-06-30
US5276057A (en) 1994-01-04
AU7395791A (en) 1992-03-05
JP2819072B2 (ja) 1998-10-30
GR3022971T3 (en) 1997-06-30
DE69131386D1 (de) 1999-07-29
EP0473252A3 (en) 1992-08-05
EP0473252B1 (en) 1997-03-05
CA2039194C (en) 1997-01-28

Similar Documents

Publication Publication Date Title
ES2135123T3 (es) Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos.
AR240048A1 (es) Derivados 5-oximicos de milbemicinas, excluidos su uso sobre o en seres humanos o animales superiores.
MX165166B (es) Mejoras en sistema ultrasonico para determinar el perfil, de cuerpos macizos
ES510134A0 (es) Levitacionario para la flotacion de seres humanos en el aire.
SE503436C2 (sv) Pyroglutamidderivat
ES2082587T3 (es) El uso de l-deprenyl para la fabricacion de un medicamento para el tratamiento de la enfermedad de cushing.
DE3851456D1 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
ATE107648T1 (de) 1-carbacephalosporin-antibiotika.
ES2094240T3 (es) Utilizacion de diol diesteres en los alimentos para perros y gatos.
ES496571A0 (es) Perfeccionamientos en dispositivos de lecho fluidizado para el tratamiento de particulas de sustancias solidas
BR9812489A (pt) Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes
ES1002871Y (es) Carro-jaula para el transporte de pequenos animales
ES294719Y (es) Dispositivo de accionamiento para el mecanismo de abatimiento del respaldo en butacas
ES1010028Y (es) Aparato para escurrir las bayetas de limpiar el suelo.
ES1017079Y (es) Receptaculo para el destete precoz de lechones.
MX9201735A (es) Composicion farmaceutica para el tratamiento y profilaxis de inflamacion y dolor en mamiferos.
ES293231Y (es) Jaula para el transporte de aves de granja
ES1007395Y (es) Dispositivo para la preparacion de pescados de la especie carangidae.
ES1008041Y (es) Dispositivo para el transporte de objetos alargados.
ES235423Y (es) Dispositivo para la cria de ostras en parques flotantes.
MX164684B (es) Sustituto de leche para alimentacion animal y procedimiento para preparar el mismo
ES285318Y (es) Tapete perfeccionado para el juego del mus
IT1171125B (it) Composizione per uso orale particolarmente destinata al trattamento terapeutico di animali
ES1017901Y (es) Dispositivo para restringir el retorno sanguineo desde el pene.
ES1016687Y (es) Dispositivo para facilitar el volcamiento de objetos pesados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 732101

Country of ref document: ES